Builds integrated diabetes-management systems, including insulin pumps, glucose monitors, dosing software and services, for people with diabetes and their healthcare providers.
10-K for FY2026, filed Jun 29, 2026We serve PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. We address this…View ↗
Our platform of simple and clinically effective solutions for PWD requiring insulin therapy includes:View ↗
Automated Insulin Delivery (AID) Systems: Integrated solutions for glucose sensing and automated insulin dosing and administration…View ↗
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the…View ↗
Sells pumps, pens, glucose monitors, consumables and software to individuals, distributors, healthcare providers and institutions worldwide; customers generally pay when products ship or are delivered. Training and care-management services are paid as delivered.
10-K for FY2026, filed Jun 29, 2026
FY2026 revenue by product or service ↗$3.1B
10-K for FY2026, filed Jun 29, 2026
$3.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Pumps
Sold outright
10-K for FY2026, filed Jun 29, 2026 |
18% |
Pumps, FY2026
$546M Sources
|
Sold outright |
|
Consumables
Sold outright
10-K for FY2026, filed Jun 29, 2026 |
31% |
Consumables, FY2026
$956M Sources
|
Sold outright |
|
CGM
Sold outright
10-K for FY2026, filed Jun 29, 2026 |
50% |
CGM, FY2026
$1.6B Sources
|
Sold outright |
|
Other
Sold outright
|
1.5% |
Other, FY2026
$46M Sources
|
Sold outright |
Individuals, healthcare providers and institutions around the world buy diabetes-management products. In the United States, MiniMed sells mainly directly to patients and also through independent distributors; sales outside the United States vary by market.
No. It lost $333M in FY2026.
10-Q for Q1 FY2027, filed Sep 8, 2026
$0View ↗
8-K, filed Nov 16, 2026
Because the charge was not contemplated in MiniMed's previously issued fiscal year 2027 adjusted EBITDA margin guidance, MiniMed is…View ↗
8-K, filed Oct 16, 2026
On October 15, 2026, the previously announced exchange offer (the “Exchange Offer”) of up to an aggregate of 252,813,348 newly issued…View ↗
8-K, filed Sep 1, 2026
Organic revenue growth of approximately 10.5%, which includes the approximate 1.0 to 1.5% benefit from the extra week in Q1 FY27, a raise…View ↗
Competes with Beta Bionics, Dexcom, Insulet, Sequel Med Tech, Tandem Diabetes Care, Ypsomed, and Medtrum
10-K for FY2026, filed Jun 29, 2026The product lines in which we compete include the components of our AID systems, including insulin pumps like the MiniMed 780G and MiniMed…View ↗
Loading...